Hoederath A, Sack H, Stuschke M, Lampka E
Strahlenklinik, Universitätsklinikum Essen.
Strahlenther Onkol. 1996 Jul;172(7):356-66; discussion 367-8.
To evaluate the long-term outcome of patients with limited-stage primary extranodal lymphoma of head and neck treated with definitive radiotherapy in low-grade and a combined radio- and chemotherapy in high-grade lymphoma.
Between January 1986 and August 1993, 63 patients with primary extranodal Non-Hodgkin lymphoma of head and neck region, stages IE and IIE were treated with radiotherapy. The histological classification followed the Kiel classification, staging the Ann Arbor classification.
33 male, 30 female; age 18 to 84 years; tumor localisation: tonsils 26, nasopharynx 7, oropharynx 8, paranasal sinus 11, salivary glands 7, floor of mouth/gingiva 3, larynx 1. Mean follow-up is 74 months. Low-grade lymphoma in stages I and II CS were treated with definitive radiation therapy according to the concepts of epithelial tumors of the same localisation (target volume and technique). The adjuvant dose was 30 Gy and in the tumor volume 40 Gy, 2 Gy daily. 28 patients were registered, 18 in stage I and 10 in stage II. High-grade lymphoma were treated with definitive radiation therapy according to the concepts of epithelial tumors of the same localisation, too. The dose was 40 respectively 50 Gy, followed by 4 courses of adjuvant chemotherapy with CHOP. Thirty-five patients were enrolled, of whom only 10 received chemotherapy.
The overall 5-year survival rates were for low-grade 67% and for high grade lymphoma 88%. The corresponding relapse-free survival rates were 54/68%, respectively. Only 1 patient failed within the irradiated target volume. Recurrences occurred at sites distant to the irradiated volume in nodal and extranodal regions. Prognosis was influenced by histologic grade. Significant trends were not observed for other potential pretreatment parameters (age, stage, localisation, bulk).
In stage I or II patients with low malignant non-Hodgkin's lymphoma of the head and neck, initial management with definitive external radiotherapy is appropriate and probably curative. In high-grade lymphoma of clinical stage IE with nonextensive tumor size definitive radiotherapy is possible in curative intention. Primary chemotherapy followed by radiation is probably preferable.
评估采用根治性放疗治疗低度恶性头颈部原发性结外淋巴瘤患者以及采用放疗联合化疗治疗高度恶性淋巴瘤患者的长期疗效。
1986年1月至1993年8月期间,63例头颈部原发性结外非霍奇金淋巴瘤IE期和IIE期患者接受了放射治疗。组织学分类采用基尔分类法,分期采用安阿伯分类法。
男性33例,女性30例;年龄18至84岁;肿瘤部位:扁桃体26例,鼻咽7例,口咽8例,鼻窦11例,唾液腺7例,口底/牙龈3例,喉1例。平均随访时间为74个月。I期和II期CS的低度恶性淋巴瘤根据相同部位上皮肿瘤的概念(靶区体积和技术)采用根治性放射治疗。辅助剂量为30 Gy,肿瘤体积剂量为40 Gy,每日2 Gy。登记患者28例,其中I期18例,II期10例。高度恶性淋巴瘤也根据相同部位上皮肿瘤的概念采用根治性放射治疗。剂量分别为40 Gy和50 Gy,随后进行4个疗程的CHOP辅助化疗。纳入患者35例,其中仅10例接受了化疗。
低度恶性淋巴瘤的5年总生存率为67%,高度恶性淋巴瘤为88%。相应的无复发生存率分别为54%/68%。仅1例患者在照射靶区内治疗失败。复发发生在照射野以外的淋巴结和结外区域。预后受组织学分级影响。未观察到其他潜在预处理参数(年龄、分期、部位、瘤体大小)有显著趋势。
对于I期或II期头颈部低恶性非霍奇金淋巴瘤患者,初始采用根治性外照射治疗是合适的,且可能治愈。对于临床IE期、肿瘤范围不广泛的高度恶性淋巴瘤,根治性放疗有可能治愈。先进行初始化疗再放疗可能更可取。